06.03 Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy

Autor: J Wienke, LL Visser, WM Kholosy, KM Keller, M Barisa, S Munnings-Tomes, E Carlton, E Poon, A Rodriguez, R Bernardi, F van den Ham, SR van Hooff, KPS Langenberg, FCP Holstege, L Chesler, J Anderson, HN Caron, T Margaritis, MM van Noesel, JJ Molenaar

Publikováno v: Oral Presentations.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a02d402af2a3666b7e059a1c6bb14db2
https://doi.org/10.1136/jitc-2022-itoc9.3

Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy.

Autor: Wienke J; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Electronic address: j.wienke-4@prinsesmaximacentrum.nl., Visser LL; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Kholosy WM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Keller KM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Barisa M; Cancer Section, Developmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health, London, UK., Poon E; Division of Clinical Studies, The Institute of Cancer Research, London, UK., Munnings-Tomes S; Cancer Section, Developmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health, London, UK., Himsworth C; Cancer Section, Developmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health, London, UK., Calton E; Division of Clinical Studies, The Institute of Cancer Research, London, UK., Rodriguez A; Hoffman-La Roche, Basel, Switzerland., Bernardi R; Genentech, A Member of the Roche Group, South San Francisco, CA, USA., van den Ham F; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., van Hooff SR; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Matser YAH; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Tas ML; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Langenberg KPS; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Lijnzaad P; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Borst AL; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Zappa E; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Bergsma FJ; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Strijker JGM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Verhoeven BM; Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden., Mei S; Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA., Kramdi A; Institut Curie, Inserm U830, PSL Research University, Diversity and Plasticity of Childhood Tumors Lab, Paris, France; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France., Restuadi R; Infection, Immunity and Inflammation Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK; NIHR Biomedical Research Centre, Great Ormond Street Hospital, London, UK., Sanchez-Bernabeu A; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; Netherlands Proteomics Centre, Utrecht University, Utrecht, the Netherlands., Cornel AM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Center for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands., Holstege FCP; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Gray JC; Centre for Cancer Immunology, University of Southampton, Southampton, UK., Tytgat GAM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Scheijde-Vermeulen MA; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Wijnen MHWA; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Dierselhuis MP; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Straathof K; University College London (UCL) Great Ormond Street Institute of Child Health, London, UK; UCL Cancer Institute, London, UK., Behjati S; Wellcome Sanger Institute, Hinxton, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Department of Paediatrics, University of Cambridge, Cambridge, UK., Wu W; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; Netherlands Proteomics Centre, Utrecht University, Utrecht, the Netherlands; Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A∗STAR), Singapore, Singapore; Department of Pharmacy, National University of Singapore, Singapore, Singapore., Heck AJR; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; Netherlands Proteomics Centre, Utrecht University, Utrecht, the Netherlands., Koster J; Amsterdam UMC location University of Amsterdam, Center for Experimental and Molecular Medicine, Amsterdam, the Netherlands., Nierkens S; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Center for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands., Janoueix-Lerosey I; Institut Curie, Inserm U830, PSL Research University, Diversity and Plasticity of Childhood Tumors Lab, Paris, France; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France., de Krijger RR; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Baryawno N; Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden., Chesler L; Division of Clinical Studies, The Institute of Cancer Research, London, UK., Anderson J; Cancer Section, Developmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health, London, UK; Department of Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, England, UK., Caron HN; Hoffman-La Roche, Basel, Switzerland., Margaritis T; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., van Noesel MM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Division Imaging & Cancer, University Medical Center Utrecht, Utrecht, the Netherlands., Molenaar JJ; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.

Publikováno v: Cancer cell [Cancer Cell] 2024 Feb 12; Vol. 42 (2), pp. 283-300.e8. Date of Electronic Publication: 2024 Jan 04.

Single-cell transcriptomics reveals immune suppression and cell states predictive of patient outcomes in rhabdomyosarcoma.

Autor: DeMartino J; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Oncode Institute, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands., Meister MT; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Oncode Institute, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands., Visser LL; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands., Brok M; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Oncode Institute, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands., Groot Koerkamp MJA; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Oncode Institute, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands., Wezenaar AKL; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Oncode Institute, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands., Hiemcke-Jiwa LS; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., de Souza T; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Oncode Institute, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands., Merks JHM; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands., Rios AC; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Oncode Institute, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands., Holstege FCP; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Center for Molecular Medicine, UMC Utrecht and Utrecht University, Universiteitsweg 100, 3584 CG, Utrecht, the Netherlands., Margaritis T; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands. A.Margaritis-2@prinsesmaximacentrum.nl., Drost J; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands. J.Drost@prinsesmaximacentrum.nl.; Oncode Institute, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands. J.Drost@prinsesmaximacentrum.nl.

Publikováno v: Nature communications [Nat Commun] 2023 May 27; Vol. 14 (1), pp. 3074. Date of Electronic Publication: 2023 May 27.

Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.

Autor: Lips EH; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Kumar T; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA., Megalios A; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK., Visser LL; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Sheinman M; Division of Molecular Carcinogenesis, Oncode Institute and The Netherlands Cancer Institute, Amsterdam, The Netherlands., Fortunato A; School of Life Sciences, Arizona State University, Tempe, AZ, USA.; Biodesign Center for Biocomputing, Security and Society, Arizona State University, Tempe, AZ, USA., Shah V; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK., Hoogstraat M; Division of Molecular Carcinogenesis, Oncode Institute and The Netherlands Cancer Institute, Amsterdam, The Netherlands., Sei E; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mallo D; School of Life Sciences, Arizona State University, Tempe, AZ, USA.; Biodesign Center for Biocomputing, Security and Society, Arizona State University, Tempe, AZ, USA., Roman-Escorza M; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK., Ahmed AA; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK., Xu M; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., van den Belt-Dusebout AW; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Brugman W; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Casasent AK; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Clements K; Screening Quality Assurance Service, Public Health England, London, UK., Davies HR; Early Cancer Unit, Hutchison/MRC Research Centre and Academic Department of Medical Genetics, Cambridge Biomedical Research Campus, University of Cambridge, Cambridge, UK., Fu L; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Grigoriadis A; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK., Hardman TM; Department of Surgery, Duke University School of Medicine, Durham, NC, USA., King LM; Department of Surgery, Duke University School of Medicine, Durham, NC, USA., Krete M; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Kristel P; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., de Maaker M; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Maley CC; Biodesign Center for Biocomputing, Security and Society, Arizona State University, Tempe, AZ, USA., Marks JR; Department of Surgery, Duke University School of Medicine, Durham, NC, USA., Menegaz BA; Department of Surgery, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA., Mulder L; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Nieboer F; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Nowinski S; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK., Pinder S; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK., Quist J; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK., Salinas-Souza C; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK., Schaapveld M; Division of Psychosocial research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Schmidt MK; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Shaaban AM; Queen Elizabeth Hospital Birmingham and University of Birmingham, Birmingham, UK., Shami R; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK., Sridharan M; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK., Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Stobart H; Independent Cancer Patients' Voice, London, UK., Collyar D; Patient Advocates in Research, Danville, CA, USA., Nik-Zainal S; Early Cancer Unit, Hutchison/MRC Research Centre and Academic Department of Medical Genetics, Cambridge Biomedical Research Campus, University of Cambridge, Cambridge, UK., Wessels LFA; Division of Molecular Carcinogenesis, Oncode Institute and The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Faculty of Electrical Engineering, Mathematics, and Computer Science, Delft University of Technology, Delft, The Netherlands., Hwang ES; Department of Surgery, Duke University School of Medicine, Durham, NC, USA., Navin NE; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Futreal PA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Thompson AM; Department of Surgery, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA., Wesseling J; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Divisions of Diagnostic Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., Sawyer EJ; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK. elinor.sawyer@kcl.ac.uk.

Publikováno v: Nature genetics [Nat Genet] 2022 Jun; Vol. 54 (6), pp. 850-860. Date of Electronic Publication: 2022 Jun 09.

Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification.

Autor: Van Bockstal MR; Department of Pathology, Erasmus MC Cancer Institute Rotterdam, The Netherlands., Agahozo MC; Department of Pathology, Erasmus MC Cancer Institute Rotterdam, The Netherlands., van Marion R; Department of Pathology, Erasmus MC Cancer Institute Rotterdam, The Netherlands., Atmodimedjo PN; Department of Pathology, Erasmus MC Cancer Institute Rotterdam, The Netherlands., Sleddens HFBM; Department of Pathology, Erasmus MC Cancer Institute Rotterdam, The Netherlands., Dinjens WNM; Department of Pathology, Erasmus MC Cancer Institute Rotterdam, The Netherlands., Visser LL; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Lips EH; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Wesseling J; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van Deurzen CHM; Department of Pathology, Erasmus MC Cancer Institute Rotterdam, The Netherlands.

Publikováno v: Molecular oncology [Mol Oncol] 2020 Apr; Vol. 14 (4), pp. 671-685. Date of Electronic Publication: 2020 Mar 05.